- Posted April 08, 2014
- Tweet This | Share on Facebook
Supreme Court takes up drug company dispute

WASHINGTON (AP) -- The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.
The justices agreed last week to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone.
The appeals court ruling would allow rivals Mylan Inc., Momenta Pharmaceuticals Inc. and Sandoz, Inc., to start selling generic versions of the drug later this year, after the remaining patents on the drug expire.
A federal district court had earlier ruled in Teva's favor and upheld the patents. Teva says the federal circuit should have deferred to factual findings made in the district court.
The justices will hear the case in the fall.
Published: Tue, Apr 8, 2014
headlines Oakland County
headlines National
- Summit offered research-based roadmap for law firms seeking to implement generative AI
- ACLU and BigLaw firm use ‘Orange is the New Black’ in hashtag effort to promote NY jail reform
- Former Wisconsin Supreme Court justice agrees to license suspension for alleged election-review misconduct
- ‘Stay out of my shorts,’ other discourteous comments led to censure for New York judge
- Federal judge’s Columbia clerk boycott didn’t harm public confidence in judiciary, judicial council rules
- ‘There is no question that we will fight,’ says latest law firm targeted in Trump executive order